Clinical Trials Directory

Trials / Completed

CompletedNCT02389556

Serum ANGPTL3, ANGPTL8 and Glypican 4 Concentrations in Relation to the Development of Obesity in Korean Children

Serum ANGPTL3, ANGPTL8 and Glypican 4 Concentrations in Relation to the Development of Obesity in Korean Children: a Three Year Prospective Cohort Study

Status
Completed
Phase
Study type
Observational
Enrollment
457 (actual)
Sponsor
Korea University · Academic / Other
Sex
All
Age
9 Years – 12 Years
Healthy volunteers
Accepted

Summary

ANGPTL3 and ANGPTL8 are emerging molecules involving lipid metabolism. In previous in vivo study using mice, ANGPTL8 regulated the activation of ANGPTL3 which was known to inhibit lipoprotein lipase activity and stimulate lipolysis of adipose tissue. Besides, glypican 4 was identified as a novel adipokine modulating adipocyte differentiation. Thus, the investigators postulated that different serum concentrations of ANGPTL3, ANGPTL8 and glypican 4 might affect progression of obesity in children. The investigators measure these molecules in Korean children, and investigate the association between these molecules and development of obesity.

Detailed description

Participants in this study were selected from the Korean Metabolic disorders \& Obesity Study in Elementary School children (KMOSES), the main aim of which was to comprehensively assess obesity-related metabolic risk factors and to evaluate clinical outcomes in Korean children prospectively. Korean children who were participated in a school-based health examination, were reexamined for the 3-year follow-up assessment.

Conditions

Timeline

Start date
2006-01-01
Primary completion
2011-12-01
Completion
2011-12-01
First posted
2015-03-17
Last updated
2016-03-01

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02389556. Inclusion in this directory is not an endorsement.